Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Wu, Xidong ^a   Liang, Huiyu ^a   Tan, Yan ^a   Yuan, Chao ^a   Li, Shuji ^a   Li, Xiaowen ^a   Li, Guiping ^a   Shi, Yusheng ^a   Zhang, Xingmei ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III; LIGAND; RHENIUM 188; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL STRAIN U87MG; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

EID: 84897124327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090752     Document Type: Article

References (26)

1. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, et al. (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26: 756-784.
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, et al. (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193.
3. Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
4. Gan HK, Cvrljevic AN, Johns TG (2013) The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS Journal 280: 5350-5370.
5. Wykosky J, Fenton T, Furnari F, Cavenee WK (2011) Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer 30: 5-12.
6. Boockvar JA, Kapitonov D, Kapoor G, Schouten J, Counelis GJ, et al. (2003) Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci 24: 1116-1130. (Pubitemid 38091521)
7. Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, et al. (2006) Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 66: 867-874. (Pubitemid 43165952)
8. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, et al. (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69: 4252-4259.
9. Mankoff DA (2007) A definition of molecular imaging. J Nucl Med 48: 18N, 21N.
10. Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550.
11. Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W (2010) Development of DNA aptamers using Cell-SELEX. Nature protocols 5: 1169-1185.
12. Shi H, Cui W, He X, Guo Q, Wang K, et al. (2013) Whole cell-SELEX aptamers for highly specific fluorescence molecular imaging of carcinomas in vivo. PLoS One 8: e70476.
13. Shi H, Tang Z, Kim Y, Nie H, Huang YF, et al. (2010) In vivo fluorescence imaging of tumors using molecular aptamers generated by cell-SELEX. Chem Asian J 5: 2209-2213.
14. Jeong JM, Knapp FF, Jr. (2008) Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy. Semin Nucl Med 38: S19-29. (Pubitemid 351163190)
15. Lambert B, Bacher K, Defreyne L (2009) Rhenium-188 based radiopharmaceuticals for treatment of liver tumours. Q J Nucl Med Mol Imaging 53: 305-310.
16. Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, et al. (2005) 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med 46: 60-66. (Pubitemid 43085999)
17. Lepareur N, Ardisson V, Noiret N, Garin E (2012) (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside. Int J Mol Imaging 2012: 278306.
18. Argyrou M, Valassi A, Andreou M, Lyra M (2013) Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy. Int J Mol Imaging 2013: 290750.
19. Zhan Y, O'Rourke DM (2004) SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res 64: 8292-8298. (Pubitemid 39491767)
20. Cheng Y, Morshed RA, Auffinger B, Tobias AL, Lesniak MS (2013) Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev.
21. Tao F, Johns RA (2010) Tat-Mediated Peptide Intervention in Analgesia and Anesthesia. Drug Dev Res 71: 99-105.
22. Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM (2013) An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers. J Drug Target.
23. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, et al. (2006) Tumor targeting by an aptamer. J Nucl Med 47: 668-678. (Pubitemid 46768469)
24. Pieve CD, Perkins AC, Missailidis S (2009) Anti-MUC1 aptamers: radiolabelling with (99 m)Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl Med Biol 36: 703-710.
25. Da Rocha Gomes S, Miguel J, Azema L, Eimer S, Ries C, et al. (2012) (99 m)Tc-MAG3-aptamer for imaging human tumors associated with high level of matrix metalloprotease-9. Bioconjug Chem 23: 2192-2200.
26. Hosseinimehr SJ, Tolmachev V, Orlova A (2012) Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today 17: 1224-1232.